media – Page 591 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

In vitro diagnostics market value to reach $ 69 billion in 2024, says Global Data

The overall market value of in vitro diagnostics (IVD) stands at $52 billion this year, and is projected to grow at a compound annual growth rate (CAGR) of 4.2% to $69 billion in 2024. According to GlobalData, a leading data and analytics company.
- Source: news.mit
- 444
- December 12, 2017
CAGR healthcare IVD Market Views
Medical sensors market worth $15.01 billion by 2022

The global medical sensors market is estimated to reach $15.01 billion by 2022, at a CAGR of 8.5% between 2016 and 2022. People are increasingly adopting home healthcare services owing to the rising costs of medical treatments in hospitals and medical care clinics. With this, the demand for various healthcare devices is expected to increase in the next few years.
- Source: todaysmedicaldevelopments
- 421
- December 12, 2017
Market Views medical sensors
Gottlieb Announces More Regulatory Updates to Encourage Device Innovation

Less than a week after announcing 3 new guidance documents to streamline the review of digital health, the FDA is moving to refine its 510(k) medical device approval pathway.
- Source: hcanews
- 516
- December 12, 2017
digital health medical device Policy
Gene therapy shows promise against blood-clotting disease

Gene therapy has freed 10 men from nearly all symptoms of hemophilia for a year so far, in a study that fuels hopes that a one-time treatment can give long-lasting help and perhaps even cure the blood disease.
- Source: Usnews
- 518
- December 12, 2017
blood disease gene hemophilia
Alexion and Halozyme Enter License Agreement for ENHANZE Technology

Alexion Pharmaceuticals, Inc. (ALXN) and Halozyme Therapeutics, Inc. (HALO) announced a collaboration and license agreement that enables Alexion to use Halozyme’s ENHANZE® drug-delivery technology in the development of subcutaneous formulations for their portfolio of products. The agreement provides Alexion with the opportunity for exclusive development of up to four targets, including a next generation subcutaneous formulation of ALXN1210 (ALXN1210 SC), the company’s investigational long-acting C5 complement inhibitor, to potentially further extend the dosing interval of ALXN1210 SC to once every two weeks or once per month.
- Source: news.alexionpharma
- 498
- December 12, 2017
ALXN1210 formulation inhibitor Market Views
Philippines halts sale of Sanofi’s dengue vaccine

The Philippines has suspended the sale and distribution of Sanofi’s dengue vaccine, authorities said on Tuesday, after the French pharmaceutical giant last week warned it could worsen symptoms for people who had not previously been infected.
- Source: Thenews
- 759
- December 12, 2017
Dengvaxia vaccine Sanofi’s dengue vaccine
Type 2 diabetes may be reversible suggests new research

A UK trial study has found that type 2 diabetes could potentially be reversed through weight loss, and with the long-term support of a medical professional.
- Source: msn.com
- 522
- December 12, 2017
diabetes weight loss
Health2Sync raises $6M to expand its diabetes tracking and management service in Asia

Health2Sync, a Taiwan-headquartered company that offers a diabetes tracking service, has closed a $6 million Series B round aimed at expanding its business in Japan and other markets in Asia.
- Source: drugdu
- 495
- December 11, 2017
diabetes diabetes tracking service Health2Sync Series
Stratasys Releases Line of Custom Built 3D Printed Anatomy Models

Stratasys, one of the big 3D printing companies, has announced the release of its new BioMimics line of 3D printed human anatomy models. The products are designed to be used in clinical training and to help design and test new medical devices.
- Source: medgadget
- 448
- December 11, 2017
anatomy Market Views model vascular
Sage Therapeutics Erupts as Depression Drug Wows in Mid-Stage Study

Shares of Sage Therapeutics have shot up more than 75 percent this morning after the company announced positive topline results for its Phase II treatment for patients with moderate to severe major depressive disorder (MDD).
- Source: Biospace
- 506
- December 11, 2017
Clinical Trials MDD SAGE-217

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.